-transparent.png){kind=logo}
A structure-activity study was performed to examine the role of position 14 of human alpha-calcitonin gene-related peptide (h-alpha-CGRP) in activating the CGRP receptor. Interestingly, position 14 of h-alpha-CGRP contains a glycyl residue and is part of an alpha-helix spanning residues 8-18. Analogues [Ala14]-h-alpha-CGRP, [Aib14]-h-alpha-CGRP, [Asp14]-h-alpha-CGRP, [Asn14]-h-alpha-CGRP, and [Pro14]-h-alpha-CGRP were synthesized by solid phase peptide methodology and purified by RP-HPLC. Secondary structure was measured by circular dichroism spectroscopy. Agonist activities were determined as the analogues' ability to stimulate amylase secretion from guinea pig pancreatic acini and to relax precontracted porcine coronary arteries. Analogues [Ala14]-h-alpha-CGRP, [Aib14]-h-alpha-CGRP, [Asp14]-h-alpha-CGRP, and [Asn14]-h-alpha-CGRP, all containing residues with a high helical propensity in position 14, were potent full agonists compared to h-alpha-CGRP in both tissues. Interestingly, replacement of Gly14 of h-alpha-CGRP with these residues did not substantially increase the helical content of these analogues. [Pro14]-h-alpha-CGRP, predictably, has significantly lower helical content and is a 20-fold less potent agonist on coronary artery, known to contain CGRP-1 receptor subtypes, and an antagonist on pancreatic acini, known to contain CGRP-2 receptor subtypes. In conclusion, the residue in position 14 plays a structural role in stabilizing the alpha-helix spanning residues 8-18. The alpha-helix is crucial for maintaining highly potent agonist effects of h-alpha-CGRP at CGRP receptors. The wide variety of functional groups that can be tolerated in position 14 with no substantial modification of agonist effects suggests the residue in this position is not in contact with the CGRP receptor. [Pro14]-h-alpha-CGRP may be a useful pharmacological tool to distinguish between CGRP-1 and CGRP-2 receptor subtypes.
J Li, and
J E Matsuura, and
D J Waugh, and
T E Adrian, and
P W Abel, and
M C Manning, and
D D Smith
August 1990,
The Biochemical journal,
J Li, and
J E Matsuura, and
D J Waugh, and
T E Adrian, and
P W Abel, and
M C Manning, and
D D Smith
December 1989,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
J Li, and
J E Matsuura, and
D J Waugh, and
T E Adrian, and
P W Abel, and
M C Manning, and
D D Smith
February 2012,
Chemical biology & drug design,
J Li, and
J E Matsuura, and
D J Waugh, and
T E Adrian, and
P W Abel, and
M C Manning, and
D D Smith
January 2001,
DNA sequence : the journal of DNA sequencing and mapping,
J Li, and
J E Matsuura, and
D J Waugh, and
T E Adrian, and
P W Abel, and
M C Manning, and
D D Smith
December 2013,
British journal of pharmacology,
J Li, and
J E Matsuura, and
D J Waugh, and
T E Adrian, and
P W Abel, and
M C Manning, and
D D Smith
February 1986,
Biochemical and biophysical research communications,
J Li, and
J E Matsuura, and
D J Waugh, and
T E Adrian, and
P W Abel, and
M C Manning, and
D D Smith
January 1991,
European journal of pharmacology,
J Li, and
J E Matsuura, and
D J Waugh, and
T E Adrian, and
P W Abel, and
M C Manning, and
D D Smith
September 1984,
Biochemical and biophysical research communications,
J Li, and
J E Matsuura, and
D J Waugh, and
T E Adrian, and
P W Abel, and
M C Manning, and
D D Smith
September 1986,
Chemical & pharmaceutical bulletin,
J Li, and
J E Matsuura, and
D J Waugh, and
T E Adrian, and
P W Abel, and
M C Manning, and
D D Smith
July 1988,
American journal of hypertension,
